PNC Financial Services Group, Inc. Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four
PNC Financial Services Group, Inc. (PNC) had Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four of $1.00 million as of 2016-12-31, per its 8-K filed 2017-05-03.
Discontinued › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan › Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt
us-gaap:PrescriptionDrugSubsidyReceiptsYearFour1 · last filed 2017-05-03
- 2016-12-31: Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four $1.00M.
- 2015-12-31: Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four $1.00M.
- 2014-12-31: Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four $2.00M.
- 2013-12-31: Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four $2.00M.
| Period end | Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four |
|---|---|
| 2016-12-31 | $1.00M 8-K · filed 2017-05-03 |
| 2015-12-31 | $1.00M 10-K · filed 2016-02-29 |
| 2014-12-31 | $2.00M 10-K · filed 2015-03-02 |
| 2013-12-31 | $2.00M 10-K · filed 2014-03-03 |
| 2012-12-31 | $1.00M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| US BANCORP DE (USB) | United States | $90.959B | 11.48 |
| TRUIST FINANCIAL CORP (TFC) | United States | $57.636B | 10.42 |
| CAPITAL ONE FINANCIAL CORP (COF) | United States | $120.568B | 11.70 |
| HUNTINGTON BANCSHARES INC /MD/ (HBAN) | United States | $30.995B | 14.37 |
| REGIONS FINANCIAL CORP (RF) | United States | $23.232B | 11.55 |
| KEYCORP /NEW/ (KEY) | United States | $21.599B | |
| Pinnacle Financial Partners, Inc. (PNFP) | United States | $14.183B | |
| FIRST HORIZON CORP (FHN) | United States | $10.987B | 11.36 |
| UMB FINANCIAL CORP (UMBF) | United States | $10.253B | 11.50 |
| CULLEN/FROST BANKERS, INC. (CFR) | United States | $9.705B | 14.20 |